A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab
Abstract Background The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). This regimen has relatively high resp...
Saved in:
Main Authors: | Madelyn Espinosa-Cotton (Author), Elana J. Fertig (Author), Laura P. Stabile (Author), Autumn Gaither-Davis (Author), Julie E. Bauman (Author), Sandra Schmitz (Author), Katherine N. Gibson-Corley (Author), Yinwen Cheng (Author), Isaac J. Jensen (Author), Vladimir P. Badovinac (Author), Douglas Laux (Author), Andrean L. Simons (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Blefarite e tricomegalia induzidas pelo cetuximabe Blepharitis and trichomegaly induced by cetuximab
by: Paulo Ricardo Criado, et al.
Published: (2010) -
Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy
by: Wiebke Sihver, et al.
Published: (2014) -
Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017) -
Pili canaliculi caused by cetuximab - A three-dimensional ultrastructural analysis
by: Hiram Larangeira de Almeida Jr, et al.
Published: (2024) -
Evaluation of the Physicochemical and Biological Stability of Cetuximab under Various Stress Condition
by: Afsaneh Farjami, et al.
Published: (2019)